Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side‐effects in tumor patients are highly reduced. Peptide‐binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptide‐binding receptors for anti‐cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptide‐binding receptors are presented, and the ghrelin receptor and the Y₁ receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described. The essential properties of receptor‐targeting peptides are specified, and recent developments in the fields of classical peptide‐drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented.

中文翻译：

---

肽-药物偶联物靶向癌细胞上的肽结合受体

专门针对癌细胞上的细胞表面分子，可以促进靶向癌症治疗，从而有可能选择性破坏恶性细胞，同时保留健康的组织。因此，大大降低了肿瘤患者的不良副作用。肽结合受体经常在癌细胞上过表达，因此有望成为选择性肿瘤治疗的靶标。在这篇综述中，归纳了用于抗癌药物递送的肽结合受体，并着重于肽配体作为递送剂。在第一部分中，介绍了一些研究最多的肽结合受体，以及生长素释放肽受体和Y ₁受体被引入作为癌症治疗的最新靶标。此外，概述了用于靶向癌细胞的非肽小分子。在第二部分中，描述了用于在癌症治疗中递送治疗性货物的肽缀合物。明确了受体靶向肽的基本性质，并介绍了经典的肽-药物结合物与毒性剂，用于放射性核素治疗的放射性标记肽和用于硼中子俘获治疗的硼化肽领域的最新进展。